CD11c+ Cells Control Platelet Homeostasis in a Murine Bone Marrow Chimeric Atherosclerosis Model
Manuela Sauter1,2,3,4,5, Serena Gregori2,3,4,5, Harald F Langer1,2,3,4,5
1Helmholtz-Institute for Translational AngioCardioScience (HI-TAC), 68167 Mannheim, Germany.
Insights
Loss of CD11c+ cells in mice with atherosclerosis accelerates platelet production and increases circulating platelet counts, linked to elevated thrombopoietin and inflammatory signals.
Area of Science:
- Immunology
- Cardiovascular Disease
- Hematology
Background:
- Dendritic cells (DCs) are crucial immune regulators in cardiovascular disease.
- The role of DCs in platelet production and homeostasis is not fully understood.
- Previous work showed CD11c+ cell depletion accelerates atherosclerosis.
Purpose of the Study:
- To investigate if sustained CD11c+ cell loss impacts platelet production.
- To determine if CD11c+ cell loss affects systemic inflammation under atherogenic conditions.
Main Methods:
- Used CD11c-DTR bone marrow chimeric mice on an ApoE-/- background, fed a high-cholesterol diet.
- Administered diphtheria toxin to deplete CD11c+ cells over six weeks.
- Quantified platelet counts, analyzed serum cytokines/chemokines, and measured thrombopoietin (TPO) levels.
Main Results:
- Chronic CD11c+ cell depletion significantly increased circulating platelet counts.
- Observed broad inflammatory remodeling with elevated cytokines linked to megakaryopoiesis and platelet activation.
- Found significantly elevated serum TPO levels after CD11c+ cell depletion.
Conclusions:
- Loss of CD11c+ cells in this model promotes a pro-thrombopoietic state.
- Elevated platelet counts and systemic inflammation are associated with CD11c+ cell depletion.
- Identified a CD11c+ cell-TPO-platelet axis connecting immune regulation to platelet homeostasis in atherogenesis.
Abstract:
Background/Objectives: Dendritic cells (DCs) are key regulators of immune responses in cardiovascular disease, yet their role in platelet homeostasis and thrombopoiesis remains incompletely understood. We previously demonstrated that chronic depletion of CD11c+ cells accelerates atherosclerotic plaque development. The objective of this study was to determine whether sustained loss of CD11c+ cells alters platelet production and systemic inflammatory signaling under atherogenic conditions. Methods: CD11c-DTR bone marrow chimeric mice on ApoE-/- background were generated and fed a high-cholesterol diet. CD11c+ cells were depleted by repeated diphtheria toxin administration over six weeks. Circulating platelet counts were quantified by automated hematology analysis. Systemic inflammatory changes were assessed using serum cytokine and chemokine profiling, and serum thrombopoietin (TPO) levels were measured by ELISA. Results: Chronic CD11c+ cell depletion resulted in a significant increase in circulating platelet counts in ApoE-/- mice. Serum cytokine profiling revealed broad inflammatory remodeling, including increased levels of cytokines associated with megakaryopoiesis and platelet activation, such as IL-4, MCP-1, CXCL9, IL-16, and IL-1α. In parallel, serum TPO levels were significantly elevated following CD11c+ cell depletion. Conclusions: In the specific context of hyperlipidemic CD11c-DTR bone marrow chimeric mice, these findings demonstrate that loss of CD11c+ cells is associated with a pro-thrombopoietic shift, elevated platelet counts, and systemic inflammatory changes. Our data identify a CD11c+ cell-TPO-platelet axis linking immune regulation to platelet homeostasis and thrombo-inflammatory signaling under these specific atherogenic conditions.


